191 related articles for article (PubMed ID: 28097652)
41. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
42. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
43. Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression.
Zhou JX; Agborbesong E; Li LX; Li X
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499487
[No Abstract] [Full Text] [Related]
44. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
45. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway.
Mancini F; Moretti F
Cell Cycle; 2009 Dec; 8(23):3854-9. PubMed ID: 19887911
[TBL] [Abstract][Full Text] [Related]
46. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
47. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
48. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.
Liu J; Tang X; Li M; Lu C; Shi J; Zhou L; Yuan Q; Yang M
Breast Cancer Res Treat; 2013 Jul; 140(1):151-7. PubMed ID: 23793604
[TBL] [Abstract][Full Text] [Related]
49. Knockdown of E2F5 induces cell death via the TP53‑dependent pathway in breast cancer cells carrying wild‑type TP53.
Inagaki Y; Wu D; Fujiwara K; Ishizuka Y; Oguni A; Tokunaga T; Takayama T; Soma M; Fukuda N; Ozaki T; Masuda S
Oncol Rep; 2020 Nov; 44(5):2241-2252. PubMed ID: 33000282
[TBL] [Abstract][Full Text] [Related]
50. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
51. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
52. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
Wasylishen AR; Lozano G
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
[TBL] [Abstract][Full Text] [Related]
53. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
54. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
55. MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4.
Wang Q; Selth LA; Callen DF
Oncotarget; 2017 May; 8(18):29914-29924. PubMed ID: 28430625
[TBL] [Abstract][Full Text] [Related]
56. Distinct Classes of Flavonoids and Epigallocatechin Gallate, Polyphenol Affects an Oncogenic Mutant p53 Protein, Cell Growth and Invasion in a TNBC Breast Cancer Cell Line.
Kollareddy M; Martinez LA
Cells; 2021 Apr; 10(4):. PubMed ID: 33918387
[TBL] [Abstract][Full Text] [Related]
57. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
58. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
59. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
60. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
